person · Reporting owner

Phillips Gary M.

Disclosed activity across 4 companies

Tapewire entity: 39205
SEC CIK: 0001197795

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Aldeyra Therapeutics, Inc.ALDX · Entity 6839	Director	June 09, 2026	June 11, 2026
Keenova Therapeutics plcMNK · Entity 28960	Exec. VP & Chief Strategy Ofcr	January 03, 2018	January 06, 2018
ROCKET PHARMACEUTICALS, INC.ITEK · Entity 5627	Director	June 20, 2017	June 21, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aldeyra Therapeutics, Inc.

Report date June 09, 2026 · Filed June 11, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.72 · Expires 2036-06-08	Direct	70,000	Reported balance After 2026-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-09 · Grant · Acquired 70,000 · Balance 70,000 F1: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.72 · Expires 2036-06-08	Direct	6,636	Reported balance After 2026-06-09 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-09 · Grant · Acquired 6,636 · Balance 6,636 F2: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.72 · Expires 2036-06-08	Direct	4,977	Reported balance After 2026-06-09 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-09 · Grant · Acquired 4,977 · Balance 4,977 F3: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date.

F2: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date.

F3: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date.

Keenova Therapeutics plc

Report date January 03, 2018 · Filed January 06, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	21,178	Ending reported balance After 2018-01-04 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2018-01-03 · Tax withholding · Disposed 834 · Balance 21,641 Row 2 · 2018-01-04 · Tax withholding · Disposed 463 · Balance 21,178

ROCKET PHARMACEUTICALS, INC.

Report date June 20, 2017 · Filed June 21, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2027-06-19	Direct	45,000	Reported balance After 2017-06-20 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-06-20 · Grant · Acquired 45,000 · Balance 45,000 F1: This stock option award was issued pursuant to Inotek Pharmaceuticals Corporation's 2014 Stock Option and Incentive Plan. The option shall vest in equal quarterly installments at the end of each quarter following June 20, 2017 subject to continued service through such dates.

Filing footnotes · ownership attribution and instrument terms

F1: This stock option award was issued pursuant to Inotek Pharmaceuticals Corporation's 2014 Stock Option and Incentive Plan. The option shall vest in equal quarterly installments at the end of each quarter following June 20, 2017 subject to continued service through such dates.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Zyla Life Sciences

Report date May 20, 2020 · Filed May 21, 2020

Section 16 reporting ended · disclosed 2020-05-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2020-05-20 transaction · row 1 1 source row Row 1 · 2020-05-20 · Disposition to issuer · Disposed 33,620 · Balance 0 F1: Common stock and derivative securities of Zyla Life Sciences ("Issuer") were disposed of pursuant to the Agreement and Plan of Merger, dated as of March 16, 2020 (the "Merger Agreement"), by and among Issuer, Assertio Holdings, Inc. ("Parent"), Assertio Therapeutics, Inc., Alligator Merger Sub, Inc. and Zyla Merger Sub, Inc. ("Merger Sub"), pursuant to which each share of the Issuer's common stock issued and outstanding immediately prior to the effective time of the merger of Merger Sub with and into Issuer (the "Effective Time") was converted into the right to receive, and became exchangeable for, (1) 2.5 shares of Parent common stock for each share of Issuer's common stock and (2) any cash in lieu of fractional shares of Parent common stock. Parent common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time F2: . Includes unvested time-based restricted stock units representing a contingent right to receive 33,620 shares of Issuer common stock upon vesting and settlement of such time-based restricted stock units. At the Effective Time, all outstanding time-based restricted stock units of Issuer were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Parent common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Issuer common stock covered by such restricted stock unit.

Filing footnotes · ownership attribution and instrument terms

F1: Common stock and derivative securities of Zyla Life Sciences ("Issuer") were disposed of pursuant to the Agreement and Plan of Merger, dated as of March 16, 2020 (the "Merger Agreement"), by and among Issuer, Assertio Holdings, Inc. ("Parent"), Assertio Therapeutics, Inc., Alligator Merger Sub, Inc. and Zyla Merger Sub, Inc. ("Merger Sub"), pursuant to which each share of the Issuer's common stock issued and outstanding immediately prior to the effective time of the merger of Merger Sub with and into Issuer (the "Effective Time") was converted into the right to receive, and became exchangeable for, (1) 2.5 shares of Parent common stock for each share of Issuer's common stock and (2) any cash in lieu of fractional shares of Parent common stock. Parent common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time

F2: . Includes unvested time-based restricted stock units representing a contingent right to receive 33,620 shares of Issuer common stock upon vesting and settlement of such time-based restricted stock units. At the Effective Time, all outstanding time-based restricted stock units of Issuer were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Parent common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Issuer common stock covered by such restricted stock unit.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 09, 2026 Filed Jun 11, 2026 20:25 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	GrantStock Option (Right to Buy) · Derivative	4,977	$0.00 Strike: $1.72	$0.00	Disclosure SEC source: 0001193125-26-267623 · ownership.xml · derivative · entry 3 Phillips Gary M. · CIK 0001197795 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,977 Underlying: Common Stock · 4,977 shares Expires 2036-06-08 F3 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document
June 09, 2026 Filed Jun 11, 2026 20:25 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	GrantStock Option (Right to Buy) · Derivative	6,636	$0.00 Strike: $1.72	$0.00	Disclosure SEC source: 0001193125-26-267623 · ownership.xml · derivative · entry 2 Phillips Gary M. · CIK 0001197795 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,636 Underlying: Common Stock · 6,636 shares Expires 2036-06-08 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document
June 09, 2026 Filed Jun 11, 2026 20:25 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	GrantStock Option (Right to Buy) · Derivative	70,000	$0.00 Strike: $1.72	$0.00	Disclosure SEC source: 0001193125-26-267623 · ownership.xml · derivative · entry 1 Phillips Gary M. · CIK 0001197795 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2036-06-08 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document
June 10, 2025 Filed Jun 12, 2025 20:21 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	GrantStock Option (Right to Buy) · Derivative	3,619	$0.00 Strike: $2.69	$0.00	Disclosure SEC source: 0000950170-25-085419 · ownership.xml · derivative · entry 3 Phillips Gary M. · CIK 0001197795 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,619 Underlying: Common Stock · 3,619 shares Expires 2035-06-09 F3 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document
June 10, 2025 Filed Jun 12, 2025 20:21 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	GrantStock Option (Right to Buy) · Derivative	4,825	$0.00 Strike: $2.69	$0.00	Disclosure SEC source: 0000950170-25-085419 · ownership.xml · derivative · entry 2 Phillips Gary M. · CIK 0001197795 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,825 Underlying: Common Stock · 4,825 shares Expires 2035-06-09 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document
June 10, 2025 Filed Jun 12, 2025 20:21 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	GrantStock Option (Right to Buy) · Derivative	62,728	$0.00 Strike: $2.69	$0.00	Disclosure SEC source: 0000950170-25-085419 · ownership.xml · derivative · entry 1 Phillips Gary M. · CIK 0001197795 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,728 Underlying: Common Stock · 62,728 shares Expires 2035-06-09 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document
June 04, 2024 Filed Jun 6, 2024 20:06 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	GrantStock Option (Right to Buy) · Derivative	2,604	$0.00 Strike: $4.09	$0.00	Disclosure SEC source: 0000950170-24-069874 · ownership.xml · derivative · entry 3 Phillips Gary M. · CIK 0001197795 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,604 Underlying: Common Stock · 2,604 shares Expires 2034-06-03 F3 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document
June 04, 2024 Filed Jun 6, 2024 20:06 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	GrantStock Option (Right to Buy) · Derivative	3,473	$0.00 Strike: $4.09	$0.00	Disclosure SEC source: 0000950170-24-069874 · ownership.xml · derivative · entry 2 Phillips Gary M. · CIK 0001197795 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,473 Underlying: Common Stock · 3,473 shares Expires 2034-06-03 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document
June 04, 2024 Filed Jun 6, 2024 20:06 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	GrantStock Option (Right to Buy) · Derivative	40,282	$0.00 Strike: $4.09	$0.00	Disclosure SEC source: 0000950170-24-069874 · ownership.xml · derivative · entry 1 Phillips Gary M. · CIK 0001197795 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,282 Underlying: Common Stock · 40,282 shares Expires 2034-06-03 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document
September 07, 2023 Filed Sep 11, 2023 20:31 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	Exercise / conversionStock Option (Right to Buy) · Derivative	5,437	$0.00 Strike: $0.55	$0.00	Disclosure SEC source: 0000950170-23-047497 · ownership.xml · derivative · entry 2 Phillips Gary M. · CIK 0001197795 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,437 shares Expires 2023-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option is fully vested. Read SEC document
September 07, 2023 Filed Sep 11, 2023 20:31 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	Exercise / conversionCommon Stock	5,437	$0.55	$3,001.22	Disclosure SEC source: 0000950170-23-047497 · ownership.xml · nonDerivative · entry 1 Phillips Gary M. · CIK 0001197795 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,812 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 30, 2023 Filed Jul 5, 2023 21:43 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	GrantStock Option (Right to Buy) · Derivative	1,372	$0.00 Strike: $8.39	$0.00	Disclosure SEC source: 0000950170-23-031788 · ownership.xml · derivative · entry 3 Phillips Gary M. · CIK 0001197795 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,372 Underlying: Common Stock · 1,372 shares Expires 2033-06-29 F3 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document
June 30, 2023 Filed Jul 5, 2023 21:43 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	GrantStock Option (Right to Buy) · Derivative	1,829	$0.00 Strike: $8.39	$0.00	Disclosure SEC source: 0000950170-23-031788 · ownership.xml · derivative · entry 2 Phillips Gary M. · CIK 0001197795 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,829 Underlying: Common Stock · 1,829 shares Expires 2033-06-29 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document
June 30, 2023 Filed Jul 5, 2023 21:43 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	GrantStock Option (Right to Buy) · Derivative	21,222	$0.00 Strike: $8.39	$0.00	Disclosure SEC source: 0000950170-23-031788 · ownership.xml · derivative · entry 1 Phillips Gary M. · CIK 0001197795 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,222 Underlying: Common Stock · 21,222 shares Expires 2033-06-29 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document
June 07, 2022 Filed Jun 9, 2022 21:06 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	GrantStock Option (Right to Buy) · Derivative	3,479	$0.00 Strike: $3.60	$0.00	Disclosure SEC source: 0000899243-22-021634 · doc4.xml · derivative · entry 3 Phillips Gary M. · CIK 0001197795 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,479 Underlying: Common Stock · 3,479 shares Expires 2032-06-06 F3 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document
June 07, 2022 Filed Jun 9, 2022 21:06 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	GrantStock Option (Right to Buy) · Derivative	4,639	$0.00 Strike: $3.60	$0.00	Disclosure SEC source: 0000899243-22-021634 · doc4.xml · derivative · entry 2 Phillips Gary M. · CIK 0001197795 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,639 Underlying: Common Stock · 4,639 shares Expires 2032-06-06 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document
June 07, 2022 Filed Jun 9, 2022 21:06 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	GrantStock Option (Right to Buy) · Derivative	53,812	$0.00 Strike: $3.60	$0.00	Disclosure SEC source: 0000899243-22-021634 · doc4.xml · derivative · entry 1 Phillips Gary M. · CIK 0001197795 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,812 Underlying: Common Stock · 53,812 shares Expires 2032-06-06 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document
June 08, 2021 Filed Jun 10, 2021 21:46 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	GrantStock Option (Right to Buy) · Derivative	875	$0.00 Strike: $12.97	$0.00	Disclosure SEC source: 0000899243-21-023012 · doc4.xml · derivative · entry 3 Phillips Gary M. · CIK 0001197795 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 875 Underlying: Common Stock · 875 shares Expires 2031-06-07 F3 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document
June 08, 2021 Filed Jun 10, 2021 21:46 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	GrantStock Option (Right to Buy) · Derivative	1,167	$0.00 Strike: $12.97	$0.00	Disclosure SEC source: 0000899243-21-023012 · doc4.xml · derivative · entry 2 Phillips Gary M. · CIK 0001197795 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,167 Underlying: Common Stock · 1,167 shares Expires 2031-06-07 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document
June 08, 2021 Filed Jun 10, 2021 21:46 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	GrantStock Option (Right to Buy) · Derivative	13,534	$0.00 Strike: $12.97	$0.00	Disclosure SEC source: 0000899243-21-023012 · doc4.xml · derivative · entry 1 Phillips Gary M. · CIK 0001197795 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,534 Underlying: Common Stock · 13,534 shares Expires 2031-06-07 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document
June 09, 2020 Filed Jun 11, 2020 21:45 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	GrantStock Option (Right to Buy) · Derivative	3,082	$0.00 Strike: $5.02	$0.00	Disclosure SEC source: 0000899243-20-016177 · doc4.xml · derivative · entry 2 Phillips Gary M. · CIK 0001197795 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,082 Underlying: Common Stock · 3,082 shares Expires 2030-06-08 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document
June 09, 2020 Filed Jun 11, 2020 21:45 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	GrantStock Option (Right to Buy) · Derivative	26,503	$0.00 Strike: $5.02	$0.00	Disclosure SEC source: 0000899243-20-016177 · doc4.xml · derivative · entry 1 Phillips Gary M. · CIK 0001197795 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,503 Underlying: Common Stock · 26,503 shares Expires 2030-06-08 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document
May 20, 2020 Filed May 21, 2020 20:31 UTC	Zyla Life Sciences ZCOR · Entity 148990	Disposition to issuerCommon Stock	33,620	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-20-064792 · a4.xml · nonDerivative · entry 1 Phillips Gary M. · CIK 0001197795 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Common stock and derivative securities of Zyla Life Sciences ("Issuer") were disposed of pursuant to the Agreement and Plan of Merger, dated as of March 16, 2020 (the "Merger Agreement"), by and among Issuer, Assertio Holdings, Inc. ("Parent"), Assertio Therapeutics, Inc., Alligator Merger Sub, Inc. and Zyla Merger Sub, Inc. ("Merger Sub"), pursuant to which each share of the Issuer's common stock issued and outstanding immediately prior to the effective time of the merger of Merger Sub with and into Issuer (the "Effective Time") was converted into the right to receive, and became exchangeable for, (1) 2.5 shares of Parent common stock for each share of Issuer's common stock and (2) any cash in lieu of fractional shares of Parent common stock. Parent common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time F2 · kind: . Includes unvested time-based restricted stock units representing a contingent right to receive 33,620 shares of Issuer common stock upon vesting and settlement of such time-based restricted stock units. At the Effective Time, all outstanding time-based restricted stock units of Issuer were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Parent common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Issuer common stock covered by such restricted stock unit. F1 · price: Common stock and derivative securities of Zyla Life Sciences ("Issuer") were disposed of pursuant to the Agreement and Plan of Merger, dated as of March 16, 2020 (the "Merger Agreement"), by and among Issuer, Assertio Holdings, Inc. ("Parent"), Assertio Therapeutics, Inc., Alligator Merger Sub, Inc. and Zyla Merger Sub, Inc. ("Merger Sub"), pursuant to which each share of the Issuer's common stock issued and outstanding immediately prior to the effective time of the merger of Merger Sub with and into Issuer (the "Effective Time") was converted into the right to receive, and became exchangeable for, (1) 2.5 shares of Parent common stock for each share of Issuer's common stock and (2) any cash in lieu of fractional shares of Parent common stock. Parent common stock had a market value of approximately $0.80 per share at the close of market immediately prior to the Effective Time F2 · price: . Includes unvested time-based restricted stock units representing a contingent right to receive 33,620 shares of Issuer common stock upon vesting and settlement of such time-based restricted stock units. At the Effective Time, all outstanding time-based restricted stock units of Issuer were cancelled and, in exchange therefor, each former holder of any such cancelled restricted stock unit has the right to receive a number of shares of fully vested Parent common stock (rounded to the nearest whole number) equal to the product of (1) 2.5 and (2) the number of shares of Issuer common stock covered by such restricted stock unit. Read SEC document
March 04, 2020 Filed Mar 6, 2020 01:40 UTC	Zyla Life Sciences ZCOR · Entity 148990	GrantCommon Stock	13,620	$0.00	$0.00	Disclosure SEC source: 0001179110-20-003200 · edgar.xml · nonDerivative · entry 1 Phillips Gary M. · CIK 0001197795 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,620 F1 · shares: Represents restricted stock units, which vest the day prior to the Company's annual meeting of stockholders to be held in 2021. Read SEC document
June 18, 2019 Filed Jun 20, 2019 20:08 UTC	Zyla Life Sciences ZCOR · Entity 148990	GrantCommon Stock	20,000	$0.00	$0.00	Disclosure SEC source: 0001179110-19-007932 · edgar.xml · nonDerivative · entry 1 Phillips Gary M. · CIK 0001197795 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · shares: Represents restricted stock units, which vest in three equal annual installments on the first three anniversaries of the date of grant. Read SEC document
June 04, 2019 Filed Jun 6, 2019 21:36 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	GrantEmployee Stock Option (Right to Buy) · Derivative	2,204	$0.00 Strike: $7.06	$0.00	Disclosure SEC source: 0000899243-19-015822 · doc4.xml · derivative · entry 2 Phillips Gary M. · CIK 0001197795 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,204 Underlying: Common Stock · 2,204 shares Expires 2029-06-03 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document
June 04, 2019 Filed Jun 6, 2019 21:36 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	GrantEmployee Stock Option (Right to Buy) · Derivative	18,951	$0.00 Strike: $7.06	$0.00	Disclosure SEC source: 0000899243-19-015822 · doc4.xml · derivative · entry 1 Phillips Gary M. · CIK 0001197795 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,951 Underlying: Common Stock · 18,951 shares Expires 2029-06-03 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document
June 07, 2018 Filed Jun 8, 2018 20:35 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	GrantEmployee Stock Option (Right to Buy) · Derivative	1,805	$0.00 Strike: $8.35	$0.00	Disclosure SEC source: 0000899243-18-015767 · doc4.xml · derivative · entry 2 Phillips Gary M. · CIK 0001197795 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,805 Underlying: Common Stock · 1,805 shares Expires 2028-06-06 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document
June 07, 2018 Filed Jun 8, 2018 20:35 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	GrantEmployee Stock Option (Right to Buy) · Derivative	15,526	$0.00 Strike: $8.35	$0.00	Disclosure SEC source: 0000899243-18-015767 · doc4.xml · derivative · entry 1 Phillips Gary M. · CIK 0001197795 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,526 Underlying: Common Stock · 15,526 shares Expires 2028-06-06 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document
January 04, 2018 Filed Jan 6, 2018 00:25 UTC	Keenova Therapeutics plc MNK · Entity 28960	Tax withholdingOrdinary Shares	463	$23.40	$10,834.20	Disclosure SEC source: 0000950138-18-000041 · edgar.xml · nonDerivative · entry 2 Phillips Gary M. · CIK 0001197795 · Exec. VP & Chief Strategy Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,178 Read SEC document
January 03, 2018 Filed Jan 6, 2018 00:25 UTC	Keenova Therapeutics plc MNK · Entity 28960	Tax withholdingOrdinary Shares	834	$23.51	$19,607.34	Disclosure SEC source: 0000950138-18-000041 · edgar.xml · nonDerivative · entry 1 Phillips Gary M. · CIK 0001197795 · Exec. VP & Chief Strategy Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,641 Read SEC document
January 02, 2018 Filed Jan 5, 2018 00:24 UTC	Keenova Therapeutics plc MNK · Entity 28960	Tax withholdingOrdinary Shares	1,687	$23.52	$39,678.24	Disclosure SEC source: 0000950138-18-000030 · edgar.xml · nonDerivative · entry 2 Phillips Gary M. · CIK 0001197795 · Exec. VP & Chief Strategy Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,475 Read SEC document
January 02, 2018 Filed Jan 5, 2018 00:24 UTC	Keenova Therapeutics plc MNK · Entity 28960	GrantOrdinary Shares	1,540	$0.00	$0.00	Disclosure SEC source: 0000950138-18-000030 · edgar.xml · nonDerivative · entry 1 Phillips Gary M. · CIK 0001197795 · Exec. VP & Chief Strategy Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,162 F1 · shares: Vesting of performance share award granted on January 2, 2015. Read SEC document
June 20, 2017 Filed Jun 21, 2017 20:06 UTC	ROCKET PHARMACEUTICALS, INC. ITEK · Entity 5627	GrantStock Options (Right to Buy) · Derivative	45,000	$0.00 Strike: $1.80	$0.00	Disclosure SEC source: 0000899243-17-016836 · doc4.xml · derivative · entry 1 Phillips Gary M. · CIK 0001197795 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2027-06-19 F1 · derivative.exercise_date: This stock option award was issued pursuant to Inotek Pharmaceuticals Corporation's 2014 Stock Option and Incentive Plan. The option shall vest in equal quarterly installments at the end of each quarter following June 20, 2017 subject to continued service through such dates. Read SEC document
June 08, 2017 Filed Jun 12, 2017 21:05 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	GrantStock Option (Right to Buy) · Derivative	2,963	$0.00 Strike: $5.15	$0.00	Disclosure SEC source: 0000899243-17-016101 · doc4.xml · derivative · entry 2 Phillips Gary M. · CIK 0001197795 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,963 Underlying: Common Stock · 2,963 shares Expires 2027-06-07 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document
June 08, 2017 Filed Jun 12, 2017 21:05 UTC	Aldeyra Therapeutics, Inc. ALDX · Entity 6839	GrantStock Option (Right to Buy) · Derivative	17,776	$0.00 Strike: $5.15	$0.00	Disclosure SEC source: 0000899243-17-016101 · doc4.xml · derivative · entry 1 Phillips Gary M. · CIK 0001197795 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,776 Underlying: Common Stock · 17,776 shares Expires 2027-06-07 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document
January 04, 2017 Filed Jan 6, 2017 23:00 UTC	Keenova Therapeutics plc MNK · Entity 28960	Tax withholdingOrdinary Shares	347	$53.19	$18,456.93	Disclosure SEC source: 0000950138-17-000043 · edgar.xml · nonDerivative · entry 1 Phillips Gary M. · CIK 0001197795 · Exec. VP & Chief Strategy Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,622 Read SEC document
January 03, 2017 Filed Jan 5, 2017 02:08 UTC	Keenova Therapeutics plc MNK · Entity 28960	GrantEmployee Share Options (Right to Buy) · Derivative	36,925	$0.00 Strike: $51.73	$0.00	Disclosure SEC source: 0000950138-17-000021 · edgar.xml · derivative · entry 5 Phillips Gary M. · CIK 0001197795 · Exec. VP & Chief Strategy Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,925 Underlying: Ordinary Shares · 36,925 shares Expires 2027-01-03 F4 · derivative.exercise_date: The options vest in their entirety on January 3, 2021. Read SEC document
January 03, 2017 Filed Jan 5, 2017 02:08 UTC	Keenova Therapeutics plc MNK · Entity 28960	GrantEmployee Share Options (Right to Buy) · Derivative	43,441	$0.00 Strike: $51.73	$0.00	Disclosure SEC source: 0000950138-17-000021 · edgar.xml · derivative · entry 4 Phillips Gary M. · CIK 0001197795 · Exec. VP & Chief Strategy Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,441 Underlying: Ordinary Shares · 43,441 shares Expires 2027-01-03 F3 · derivative.exercise_date: The options vest in four equal annual installments beginning January 3, 2018. Read SEC document
January 03, 2017 Filed Jan 5, 2017 02:08 UTC	Keenova Therapeutics plc MNK · Entity 28960	GrantOrdinary Shares	7,733	$0.00	$0.00	Disclosure SEC source: 0000950138-17-000021 · edgar.xml · nonDerivative · entry 3 Phillips Gary M. · CIK 0001197795 · Exec. VP & Chief Strategy Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,969 F2 · shares: Represents restricted stock units that vest in four equal annual installments beginning January 3, 2018. Read SEC document
January 02, 2017 Filed Jan 5, 2017 02:08 UTC	Keenova Therapeutics plc MNK · Entity 28960	Tax withholdingOrdinary Shares	3,073	$49.82	$153,096.86	Disclosure SEC source: 0000950138-17-000021 · edgar.xml · nonDerivative · entry 2 Phillips Gary M. · CIK 0001197795 · Exec. VP & Chief Strategy Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,236 Read SEC document
January 02, 2017 Filed Jan 5, 2017 02:08 UTC	Keenova Therapeutics plc MNK · Entity 28960	GrantOrdinary Shares	6,732	$0.00	$0.00	Disclosure SEC source: 0000950138-17-000021 · edgar.xml · nonDerivative · entry 1 Phillips Gary M. · CIK 0001197795 · Exec. VP & Chief Strategy Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,309 F1 · shares: Vesting of performance share award granted on January 2, 2014. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.